Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) ended Friday session in green amid volatile trading. The shares closed up +0.89 points or 2.88% at $31.75 with 2.32 million shares getting traded. Post opening the session at $30.64, the shares hit an intraday low of $30.54 and an intraday high of $32.19 and the price vacillated in this range throughout the day. The company has a market cap of $3.95 billion and the numbers of outstanding shares have been calculated to be 120.92 million shares.
On Sept. 15, 2016 Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, announced that the company will present new data on the clinical characteristics, impact on quality of life and psychosocial consequences of living with familial chylomicronemia syndrome (FCS). The findings will be presented in two poster presentations at the American Society for Preventative Cardiology (ASPC) 2016 Congress being held September 16-18 in Boca Raton, Florida. These new data reflect findings from the largest study in patients with FCS conducted to date and provide new insights on the disease burden from the perspective of patients and caregivers.
“As is often the case, studies such as these in rare patient populations provide insights into the disease and the patients’ experience of their disease that are missing from the literature. While each patient’s experience of his or her disease is personal and unique, there are common symptoms uncovered, sometimes under-recognized, that build and broaden the medical community’s understanding and approach to treating the patient and his or her condition,” said Dr. Louis O’Dea, chief medical officer of Akcea. “We are committed to building a comprehensive understanding of FCS by using multiple methodologies to collect additional data relevant to patients’ experience living with FCS.”
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ended Friday session in red amid volatile trading. The shares closed down -0.02 points or -0.06% at $34.15 with 2.29 million shares getting traded. Post opening the session at $33.73, the shares hit an intraday low of $33.53 and an intraday high of $34.35 and the price vacillated in this range throughout the day. The company has a market cap of $4.09 billion and the numbers of outstanding shares have been calculated to be 119.75 million shares.
ACADIA Pharmaceuticals Inc. (ACAD) on August 24, 2016 announced that the underwriters for the Company’s previously announced public offering have fully exercised their option to purchase an additional 909,090 shares. All 6,969,696 shares sold in the offering were offered by ACADIA at a price to the public of $33.00 per share, for total gross proceeds to ACADIA of approximately $230.0 million before deducting underwriting discounts and commissions and other offering expenses payable by ACADIA. The closing of the sale of 6,060,606 shares was completed on August 15, 2016, and the closing of the sale of 909,090 shares pursuant to the full exercise by the underwriters of their option to purchase additional shares was completed earlier.